156 related articles for article (PubMed ID: 17600474)
21. Radioiodine therapy of thyroid autonomy.
Reiners C; Schneider P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S471-8. PubMed ID: 12192548
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.
Robbins RJ; Driedger A; Magner J;
Thyroid; 2006 Nov; 16(11):1121-30. PubMed ID: 17123339
[TBL] [Abstract][Full Text] [Related]
23. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
24. [Results of TcTUs-optimized radioiodine therapy in multifocal and disseminated autonomy].
Dunkelmann S; Endlicher D; Prillwitz A; Rudolph F; Groth P; Schümichen C
Nuklearmedizin; 1999; 38(5):131-9. PubMed ID: 10488479
[TBL] [Abstract][Full Text] [Related]
25. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.
Schmidt M; Gorbauch E; Dietlein M; Faust M; Stützer H; Eschner W; Theissen P; Schicha H
Thyroid; 2006 Mar; 16(3):281-8. PubMed ID: 16571091
[TBL] [Abstract][Full Text] [Related]
26. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
[TBL] [Abstract][Full Text] [Related]
27. Radioiodine therapy in thyrotoxicosis.
Taher MA; Loken MK; Bantle JP
J Indian Med Assoc; 1991 Apr; 89(4):86-8. PubMed ID: 1940400
[TBL] [Abstract][Full Text] [Related]
28. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
29. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
[TBL] [Abstract][Full Text] [Related]
30. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
[TBL] [Abstract][Full Text] [Related]
31. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
32. Transient hypothyroidism after iodine-131 treatment of thyrotoxicosis.
Sawers JS; Toft AD; Irvine WJ; Brown NS; Seth J
J Clin Endocrinol Metab; 1980 Feb; 50(2):226-9. PubMed ID: 7354108
[TBL] [Abstract][Full Text] [Related]
33. [Radioiodine therapy for thyroid cancer].
Misaki T
Nihon Rinsho; 2007 Nov; 65(11):2049-52. PubMed ID: 18018569
[TBL] [Abstract][Full Text] [Related]
34. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
36. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.
Meller J; Siefker U; Hamann A; Hüfner M
Exp Clin Endocrinol Diabetes; 2006 May; 114(5):235-9. PubMed ID: 16804797
[TBL] [Abstract][Full Text] [Related]
37. Thyroid fine-needle aspiration biopsy: which lesions should be biopsied before 131I therapy?
Listewnik MH; Birkenfeld B; Chosia M; Elbl B; Piwowarska-Bilska H; Zorga P; Niedziałkowska K
Ann Acad Med Stetin; 2011; 57(1):54-8. PubMed ID: 22593992
[TBL] [Abstract][Full Text] [Related]
38. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I
Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755
[TBL] [Abstract][Full Text] [Related]
39. The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine.
Davies PH; Franklyn JA; Daykin J; Sheppard MC
J Clin Endocrinol Metab; 1992 May; 74(5):1189-94. PubMed ID: 1569166
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
Gamstedt A; Karlsson A
J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
